RobustPDx is introduced, a dataset comprising structured motor and cognitive tasks performed remotely via an accessible web-based assessment completed by 261 participants, including 73 individuals with self-reported PD, 33 individuals reporting suspected PD, and 155 non-PD controls, each completing standardized tasks remotely using their own computer.
Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disorder associated with motor symptoms and cognitive changes. Its increasing global disease burden highlights the need for scalable approaches to support remote assessment and digital biomarker discovery. Digital health platforms offer scalable opportunities to assess motor and cognitive performance metrics relevant to PD diagnosis remotely, minimizing logistical and geographic barriers. We introduce RobustPDx, a dataset comprising structured motor and cognitive tasks performed remotely via an accessible web-based assessment completed by 261 participants, including 73 individuals with self-reported PD, 33 individuals reporting suspected PD, and 155 non-PD controls, each completing standardized tasks remotely using their own computer. The dataset includes raw task-level interaction data and a feature-engineered analytic dataset containing 79 derived features spanning five task categories related to fine motor control and working memory. Each record in the resulting dataset is paired with demographic data, device type, and handedness annotations. Notably, including device type and handedness metadata enables analyses along traditionally underexplored but important axes of variation in remote consumer digital health. Together, these data support the development and benchmarking of AI-driven models for remote PD detection and robust digital biomarker discovery.
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by deteriorating motor function and remains incurable. Diagnosis and monitoring remain largely clinical, as the pathological gold standard - post-mortem examination - is inherently impractical in routine care; the scarcity of movement di...
Yan-De Li, M. Ahmed, Fang Ba et al.· Medical Image Analysis· 0 citations
Open, multimodal, neuroimaging datasets are a key resource for the development of biomarkers and statistical models that can support disease monitoring and treatment planning in Parkinson’s disease (PD). Here we present the first release of Quebec Parkinson Network Neuroimaging Cohort (QPN-NC), a cross-sectional coho...
Nikhil Bhagwat, A. Vo, C. Degroot et al.· Scientific Data· 0 citations
Cognitive impairment is one of the most functionally debilitating non-motor symptoms in Parkinson's disease (PD). Yet, current diagnostic and clinical practices rely heavily on subjective assessments and burdensome behavioral testing, which lack the temporal resolution to detect subtle deficits. While EEG and pupillome...
Mercedes A. Terry, Samuel A. Birkholz, Jeffery S. Johnson et al.· Cognitive Neurodynamics· 0 citations
Parkinson’s disease (PD) is a heterogeneous neurodegenerative disorder marked by diverse motor and non-motor symptom profiles. Traditional symptom-based subtyping shows limited stability and lacks clear biological grounding. Integrating magnetic resonance imaging (MRI) with machine learning (ML) offers a promising aven...
A. Vijayakumari, K. Sakaie, Hubert H. Fernandez et al.· Frontiers in Aging Neuroscie...· 0 citations
According to the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder among older adults, surpassed only by Alzheimer’s disease. PD is characterized by a heterogeneous combination of motor and non-motor symptoms,...
Veronica Hernandez-Ramirez, D. Almanza-Ojeda, Oscar Almanza-Conejo et al.· Technologies· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.